Cyclodextrins in North America's pharmaceutical market are experiencing substantial growth due to their diverse roles in drug formulation. These cyclic oligosaccharides serve as molecular encapsulation agents, elevating drug solubility, stability, and bioavailability. Tackling issues linked to poor drug solubility, cyclodextrins enable the creation of more potent and easily absorbed medications. Forming stable inclusion complexes with drug molecules enhances drug delivery systems, resulting in improved therapeutic outcomes and broader opportunities for formulating drugs with complex physicochemical properties.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/north-america-cyclodextrins-in-pharma-market
Data Bridge Market Research analyses that the North America Cyclodextrins in Pharma Market which was USD 53.7 million in 2022, is expected to reach USD 70.2 million by 2030, at a CAGR of 3.4% from 2023 to 2030. Cyclodextrins play a crucial role in pharmaceuticals by masking unpleasant tastes or odors of specific drugs, significantly improving patient compliance and the overall acceptability of pharmaceutical products.
Key Findings of the Study
Increasing investment in healthcare infrastructure is expected to drive the market's growth rate
Heightened investments in healthcare infrastructure propel the growth of cyclodextrins in the pharma market. The increasing healthcare expenditure enhances facilities and resources, fostering a conducive environment for pharmaceutical advancements. This improved infrastructure supports the research, development, and production of cyclodextrin-based pharmaceuticals, facilitating their integration into the market and furthering the sector's overall growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Β Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α Cyclodextrin, γ-Cyclodextrin, Randomly Methylated Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin and 2-Hydroxypropyl-Γ-Cyclodextrin), Structure (Cyclodextrin Conjugates, Mucoadhesive Drug Carriers, Cyclodextrin Associates, Amphiphilic Cyclodextrins and Others), Nature (Hydrophilic and Hydrophobic), Form (Solid and Liquid), Application (Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability and Others), Therapeutic Areas (Pain Management, Cardiovascular Diseases, Behavioral Disorder, Cancer Therapy, Rheumatoid Arthritis, Epilepsy, Niemann Pick Disease Type C (NPC) and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America
|
|
Market Players Covered
|
Cambrex Corporation (U.S.), Cayman Chemical (U.S.), Wellona Pharma (India), Wacker Chemie AG (Germany), Tocopharm Co. Limited (China), Roquette Frères (France), Midas Pharma GmbH (Germany), Ligand Pharmaceuticals Incorporated (U.S.), Cyclo Therapeutics, Inc. (U.S.), Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Germany), Otto Chemie Pvt. Ltd. (India), VIO CHEMICALS (Switzerland), Ashland (U.S.), TCI Chemicals (India) Pvt. Ltd. (Japan)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The North America cyclodextrins in pharma market is segmented on the basis of type, structure, nature, form, application, therapeutic areas and distribution channel.
- On the basis of type, the North America cyclodextrins in pharma market is segmented into Β cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, Α cyclodextrin, γ-cyclodextrin, randomly methylated Β-cyclodextrin, sulfobutylether Β-cyclodextrin and 2-hydroxypropyl-γ-cyclodextrin
- On the basis of structure, the North America cyclodextrins in pharma market is segmented into cyclodextrin conjugates, mucoadhesive drug carriers, cyclodextrin associates, amphiphilic cyclodextrins and others
- On the basis of nature, the North America cyclodextrins in pharma market is segmented into hydrophilic and hydrophobic
- On the basis of form, the North America cyclodextrins in pharma market is segmented into solid and liquid
- On the basis of application, the North America cyclodextrins in pharma market is segmented into drug solubility and dissolution, drug bioavailability, drug safety, drug stability and others
- On the basis of therapeutic areas, the North America cyclodextrins in pharma market is segmented into pain management, cardiovascular diseases, behavioral disorder, cancer therapy, rheumatoid arthritis, epilepsy, niemann pick disease type c (NPC) and others
- On the basis of distribution channel, the North America cyclodextrins in pharma market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others
Major Players
Data Bridge Market Research recognizes the following companies as the major North America cyclodextrins in pharma market players in North America cyclodextrins in pharma market Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Germany), Otto Chemie Pvt. Ltd. (India), VIO CHEMICALS (Switzerland), Ashland (U.S.), TCI Chemicals (India) Pvt. Ltd. (Japan)
Market Developments
- In November 2019, Ligand Pharmaceuticals Incorporated showcased positive outcomes from a Phase 1 clinical trial of the Captisol Active (Iohexol) program at ASN Kidney Week 2019. The CE-Iohexol program aimed to develop Captisol-active, a diagnostic imaging agent with reduced nephrotoxicity risk. The study achieved primary endpoint equivalence, enhancing Ligand's prominence within the pharmaceutical industry and validating the potential of their innovative diagnostic imaging agent
- In December 2018, Roquette Frères forged a strategic collaboration with Thermo Fisher Scientific Inc. to distribute its drugs in the U.S. and Canada. This collaborative effort aims to capitalize on the significant growth potential in these regions, leveraging the strengths of both world leaders to enhance market presence and drive advancements in pharmaceutical distribution and innovation
- In November 2018, Wacker Chemie AG acquired SynCo Bio Partners B.V., rebranding it as Wacker Biotech B.V. The facility, specializing in pharmaceutical manufacturing, expanded Wacker's capabilities in producing medicines, live microbial products, and vaccines. This strategic acquisition bolstered Wacker's cyclodextrin production for pharmaceutical applications, contributing to an increased market share and strengthening its position in the industry
Regional Analysis
Geographically, the countries covered in the North America cyclodextrins in pharma market report are U.S., Canada and Mexico in North America.
As per Data Bridge Market Research analysis:
U.S. is the dominant region in North America cyclodextrins in pharma market during the forecast period 2023-2030
The U.S. dominates the North America equipment market, owing to many companies, robust research and development capabilities, and widespread incorporation of new cyclodextrin-based drugs in pharmacology. The nation's strong pharmaceutical sector showcases its leadership in adopting innovative technologies, fostering a dynamic landscape for cyclodextrins. With a high prevalence of cutting-edge research and pharmaceutical enterprises, the U.S. significantly influences and leads the advancement of cyclodextrin applications in the broader North American pharmaceutical market.
For more detailed information about the North America cyclodextrins in pharma market report, click here – https://www.databridgemarketresearch.com/fr/reports/north-america-cyclodextrins-in-pharma-market
